KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review. PMID 41502513 · Oncol Res · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. PMID 41476792 · Front Pharmacol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Addressing the cancer burden in LMICs: the potential of modulated electro-hyperthermia. PMID 41476580 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations. PMID 41473825 · Case Rep Oncol Med · 2025 The record is a case report (as stated in the abstract and title) of a single patient, not a randomized trial. It does not present formal results from a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. The abstract discusses the POLO trial but does not report new trial results; it is a narrative account of an individual patient's outcome on olaparib maintenance therapy.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial. PMID 41473750 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. PMID 41473225 · Front Neurol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers. PMID 41466844 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimally invasive coronary artery bypass grafting (MINI-CABG): Protocol for a pilot randomized controlled trial comparing minimally invasive versus conventional coronary surgery. PMID 41460930 · PLoS One · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy. PMID 41459523 · Front Immunol · 2025 This is a Phase II/III clinical trial (per publication_types) of intratumoral immune checkpoint inhibitors in recurrent/refractory solid tumors, which is oncologic, human, and involves a drug intervention with original results. However, it is not randomized (no mention of randomization) and lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR reporting. The abstract reports only four cases with complete responses, which is not a formal time-to-event analysis from a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of a Short-Term Advance Care Planning Intervention (VOICE) for Dialysis Patients with ESRD: A Randomized Controlled Trial. PMID 41459036 · Patient Prefer Adherence · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Home-Combo: an online home-based exercise intervention for women with breast cancer undergoing neoadjuvant chemotherapy: study protocol for a 2-arm pragmatic randomized controlled trial. PMID 41458599 · Front Oncol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Teaching Cancer Survivors Coping Skills for Managing Fear of Recurrence: Insights From a Pilot Randomized Controlled Trial. PMID 41445966 · Glob Adv Integr Med Health · 2025 This is an oncology, human, randomized, original result report, but it is excluded because it is not a Phase III/IIIb or Phase II/III trial (phase is not specified and not a drug trial), it has no time-to-event efficacy endpoint (outcomes are coping scores, not OS/PFS/DFS/EFS/RFS/TTP, and no Kaplan-Meier/HR reported), and it lacks a drug-containing intervention (intervention is a mind-body psycho-oncology program, not a drug).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrating smoking cessation support during lung cancer diagnostic workup: a pragmatic, multicenter, cluster-randomised controlled trial. PMID 41445708 · Front Health Serv · 2025 The trial is a randomized study in human lung cancer patients with original results, but it is not eligible because it lacks a drug-containing intervention and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The phase is also not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Testing oral nicotine pouches versus nicotine replacement therapy for cigarette harm reduction in Appalachia: The ARISE study protocol. PMID 41433314 · PLoS One · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial. PMID 41425742 · Clin Ophthalmol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial. PMID 41425719 · Oncol Res · 2025 The study does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Landscape Analysis of Human Papillomavirus (HPV) Prophylactic Vaccine Clinical Trials in China Based on the NMPA Database. PMID 41425496 · Drug Des Devel Ther · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Effect of Opioid-Free Anesthesia with Esketamine on Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Thoracoscopic Surgery: A Prospective, Randomized, Controlled Trial. PMID 41425495 · Drug Des Devel Ther · 2025 The record describes a randomized trial in lung cancer patients, but it fails two key eligibility criteria: (1) the primary endpoint is not a time-to-event efficacy endpoint (it is the incidence of a postoperative complication), and (2) there is no explicit evidence of a Phase III/IIIb or Phase II/III trial design. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer in the immunotherapy era: current landscape and future perspectives. PMID 41415539 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effects of narrative care combined with life review on psychological distress, meaning in life, and quality of life in advanced cancer patients receiving hospice care: a randomized clinical trial. PMID 41409070 · Front Psychol · 2025 The record describes a randomized trial of a psychosocial intervention (narrative care combined with life review) in advanced cancer patients. While it is oncology-related, human, and randomized, it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The outcomes assessed are psychological distress, meaning in life, and quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. PMID 41404513 · Front Endocrinol (Lausanne) · 2025 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Effects of Different Doses of Butorphanol on Perioperative Analgesia, Recovery, and Immune Function in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Randomized Controlled Trial. PMID 41393328 · Drug Des Devel Ther · 2025 The study is a randomized trial of a drug for perioperative pain management in ovarian cancer surgery, but it does not meet key eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial, and it lacks a time-to-event oncology efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis. PMID 41384277 · Transpl Int · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma. PMID 41383547 · Blood Lymphat Cancer · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase 1, randomized, crossover study comparing intravenous GTX-104 to oral nimodipine in healthy human subjects. PMID 41359540 · PLoS One · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial. PMID 41357893 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs. PMID 41347089 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Research trends in neoadjuvant therapy for esophageal cancer: a bibliometric and meta-analysis. PMID 41346615 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review. PMID 41341578 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. PMID 41335584 · PLoS One · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase II clinical trial of Bifidobacterium longum subsp. longum BL21 for preventing acute radiation enteritis among pelvic radiotherapy patients. PMID 41293184 · Front Nutr · 2025 The study is a phase II, single-arm, non-randomized trial evaluating a probiotic for toxicity prevention, lacking the required phase, randomization, drug intervention, and time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic effect of the traditional Chinese medicine formula danxiong granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial. PMID 41282614 · Front Pharmacol · 2025 The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Although PFS is reported, its status as a primary or key secondary endpoint is not confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study). PMID 41262296 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy. PMID 41259337 · PLoS One · 2025 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nurse led telephonic palliative care versus specialty outpatient palliative care: pragmatic, randomised clinical trial. PMID 41245582 · BMJ Med · 2025 The study is a randomized clinical trial with oncology patients (advanced cancer) and reports primary results, but it is ineligible because it lacks a drug-containing intervention (interventions are palliative care delivery models) and does not report a time-to-event efficacy endpoint. The primary outcome is change in quality of life (FACT-G score), not a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effectiveness of kinesiology taping on dysphagia in brain tumor survivors after neurosurgery: study protocol for a pilot randomized controlled trial. PMID 41244764 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer. PMID 41235190 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Closed-loop temperature management with internet of things technology support in elderly laparoscopic rectal cancer surgery: A randomised controlled trial. PMID 41231776 · PLoS One · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Is radioiodine necessary for patients with low-risk differentiated thyroid cancer after thyroidectomy: a pooled analysis of ESTIMABL2 and IoN trials. PMID 41229489 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis. PMID 41229435 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis. PMID 41221276 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ursodeoxycholic acid treatment of LPAC presenting as post cholecystectomy pain: rationale and design of a randomised trial. PMID 41216274 · Transl Gastroenterol Hepatol · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. PMID 41211586 · J Obes · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol. PMID 41210271 · Front Sports Act Living · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study. PMID 41208989 · Front Immunol · 2025 The study is a non-oncology, non-randomized observational cohort study comparing the risk of uveitis in patients with spondyloarthritis and psoriatic diseases treated with Janus kinase inhibitors versus tumor necrosis factor inhibitors. While it includes drug interventions and a time-to-event endpoint, it does not meet the core oncology or randomized trial criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial. PMID 41200184 · Front Immunol · 2025 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ethical issues in a cluster randomised controlled trial for evaluating effectiveness of screening for breast cancer by clinical breast examination in India. PMID 41195487 · Indian J Med Ethics · 2025 The record is an ethical analysis of a cluster randomized screening trial, not a report of a drug-containing oncology Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial. PMID 41185705 · Drug Des Devel Ther · 2025 The study is a randomized, controlled trial in breast cancer patients investigating a drug intervention (esketamine) for postoperative depression. However, it is not explicitly a Phase III or definitive randomized trial as required, and the primary efficacy endpoint is a depression score (HAMD-17), not a time-to-event oncology endpoint like overall survival or progression-free survival.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. PMID 41179951 · Immunotargets Ther · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Antibody-drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. PMID 41179119 · Ther Adv Med Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -